Vaccine strategies for cancer immunotherapy have focused on peptide ligands with high affinity for MHC class I. Largely, these vaccines have not been therapeutic. We have examined the peptide specificity of a strongly protective T-cell response that eradicates established B16 melanoma and find that the recognized epitope is generated by a low-affinity MHC class I ligand from tyrosinase-related protein 1 (TRP1). Cytotoxic T-cell responses are induced against TRP1 222-229 by several vaccination schemes using a Toll-like receptor agonist, T regulatory cell depletion, or the immune modulator B7-DCXAb to drive immunity. TRP1 222 CTL are generated from multiple antigen sources, including antigens expressed by tumors growing in situ, tumor cell lysates, and peptide vaccines. The key finding in this study is that protection from freshly implanted or established B16 tumors is primarily mediated by TRP1 222 -specific CTL and not by CTL specific for more traditional melanoma antigens such as TRP2 or gp100. This finding challenges the assumption that the optimal peptide antigens for cancer vaccines are high-affinity MHC ligands. We propose that when administered appropriately, native low-affinity MHC ligands are optimal inducers of immunotherapeutic CTL. [Cancer Res 2009;69(7): 
Introduction
MHC class I restricted self antigens have been selected for tumor vaccines (1-3) using the rationale that high-affinity MHC class I binding peptides will form the best antigens for eliciting tumorspecific cytotoxic lymphocytes (CTL; ref. 4) . One drawback to this approach is that strong binding self-peptides excel in promoting tolerance, leaving only low-affinity T cells as potential responders. Emerging evidence shows that T cells can target lower-affinity MHC ligands (3, (5) (6) (7) . Because these ligands have a low probability of binding MHC, the hypothesis is that only high-avidity T cells can target these peptide antigens. Latent pools of high-avidity T cells that can be primed for antitumor responses have been reported (8) . However, approaches to induce responses against these low-affinity ligands are challenging, involving overcoming tolerance using highaffinity heteroclitic peptide mimics or broad-spectrum depletion of regulatory T cells (3, 8) .
Although tumors express immunogenic determinants, they often use strategies to escape immune surveillance; these strategies do not necessarily eliminate the T cells targeting the tumor, but instead render them functionally nonresponsive. Several immunotherapeutic strategies target this population of potential effector cells (9, 10) , with the intent of reversing tolerance or immunosuppression. We have discovered an immune modulator that robustly activates endogenous CTL capable of targeting tumors (11) (12) (13) . This immune modulator B7-DC cross-linking antibody (B7-DCXAb) binds to and cross-links B7-DC on dendritic cells, leading to the generation of strong type I immune responses capable of clearing established tumors. Struck by the robust and rapid response generated against the rather nonimmunogenic B16 tumor, we investigated the target of these CTL. The finding that protective CTL respond to a very weak MHC ligand raises questions about the nature of tumor antigens that can be effectively targeted by immunotherapy and sheds light on an alternative set of natural antigens for use in tumor vaccines.
Materials and Methods
Mice. C57BL/6 mice from The Jackson Laboratory were used in compliance with Mayo Clinic Institutional Animal Care and Use Committee guidelines.
Reagents. B16-F1 (B16), C57SV, EL4, and RMAS lines were maintained using standard conditions. Transfected cell lines were maintained in geneticin (Invitrogen) supplemented medium (2.5 mg/mL). Generation of the recombinant human IgM antibody B7-DCXAb and control antibody was described (14) . Purified anti-CD25 antibody was prepared from hybridoma PC61 (American Type Culture Collection). Peptides (Supplementary Table S1 ) were manufactured by Elim Biopharmaceuticals, Inc. ODN-1826 (5 ¶-TCCATGACGTTCCTGACGTT-3 ¶; CpG) was synthesized by the Mayo Clinic Advanced Genomics Technology Center. The B16 cell lysate (B16-CL) was prepared as described (15) .
B7-DCXAb treatment protocols. Prophylactic B7-DCXAb treatment (30 Ag i.v.) was given 1 d before B16 cells (5 Â 10 5 ), gB16 (12,000 rad) cells, or B16-CL. Therapeutic treatment was administered 4 to 6 d after tumor challenge. Six days after challenge, draining lymph node cells were harvested and pooled for use in cytotoxicity assays. Adoptive transfer of B7-DCXAb-treated dendritic cells has been described (16) . Mice were monitored for tumor growth and euthanized when tumor size reached 225 mm 2 . Typically, 4-to 5-d seeded tumors were not measurable externally but could be observed surgically. By day 7, they could be measured in all mice. Tumor index was determined as the square root of the product of the tumor measured in two dimensions.
CpG immunization and CD25 depletion. Mice were injected with 100 Ag of CpG on days À2, À1, 0, +1, and +2 in the right flank and with 200 Ag of B16-CL emulsified in IFA on day 0. For T regulatory cell depletion, we injected 0.5 mg of anti-CD25 antibody i.v. on days À3 and À2. Day 7 draining lymph nodes were harvested for cytotoxicity assays. On day 7, CD4 + CD25 + cells continued to be reduced by at least 40%. TRP1 222 -and TRP2 180 -specific CTL. CTL were generated as described previously (3) . Mice were injected in the footpad with 5 Ag of peptide or 20 Ag of B16-CL emulsified in Titermax classic adjuvant (Sigma). Splenocytes were harvested 7 d later and mixed with irradiated (30 Gy) splenocytes pulsed with 1 Ag/mL of peptide for 1 h at 37jC. TRP1 222 and TRP2 180 effector cells were used in cytotoxicity assays 5 d later. Lineage specificity was performed using magnetic bead separation (Miltenyi Biotec) and MHC I restriction using blocking antibodies to H-2K b (B8-24-3) and H-2D b (B22-249.R1 and 28-14-8). Cytotoxicity assays. CTL specificity was assessed using 4-h chromium release assays. An array of peptides (Supplementary Table S1 ) pulsed onto EL4 or C57SV (10 Ag/mL) were used as targets. Where indicated, B16 tumor cells were pretreated for 18 h with 200 ng/mL of IFNg (Invitrogen). Data represent triplicate measurements F SD.
Cloning, mutagenesis, and transfection. TRP1 cDNA corresponding to bases 121-1631 (NM 031202) was cloned from B16 and ligated into the pcDNA 3.1 TOPO vector (Invitrogen). We used site-directed mutagenesis to change tyrosine 226 to alanine. C57SV cells were stably transfected with linearized cDNA using the Fugene 6 Transfection reagent (Roche Diagnostics). TRP1 expression was verified by real time reverse transcription-PCR.
RMAS stabilization assay. MHC class I stabilization assays were performed as described (17) . Briefly, H-2K b was stabilized by overnight incubation at 30jC and diluted peptides were co-incubated at 30jC for 1 h before transfer to 37jC for 4 h. H-2K b stabilization was measured by flow cytometry using anti-H-2K b antibody (B8-3-24). Peptide inhibition. We used a peptide inhibition strategy to block peptide-specific T-cell responses (18) 
Results
CTL generated with live B16 or B16 tumor cell lysate recognize the peptide TRP1 222-229 . B7-DCXAb given 1 day before B16 challenge or with B16-CL as a vaccine generates CTL that target and eliminate B16 melanoma (15) . To learn which antigens are targeted by these vaccines, we used peptide pulsed targets to screen MHC class I epitopes identified in B16 models (1, 2, 19, 20) . B7-DCXAb was administered 1 day before s.c. B16 or B16-CL and 6 days later CTL harvested from lymph nodes were tested for antigen specificity. CTL targeting B16 were observed exclusively in the draining lymph nodes (not shown), demonstrating vaccine specificity. These lymphocytes did not recognize targets presenting any of the traditionally defined B16 epitopes ( Fig. 1A ; Supplementary Fig. S1 ), but instead effectively lysed cells pulsed with TRP1 222 (Fig. 1A) , a peptide previously identified as a weak MHC class I binding ligand targeted using a heteroclitic mimic vaccine (3) . Our studies use a B16 tumor line expressing wild-type TRP1, as determined by direct sequence analysis.
Struck by the unexpected focus on a cryptic self-antigen, we sought to rule out the possibility that B7-DCXAb treatment leads to the generation of CTL that are distinctive to this immune modulator. Accordingly, we elicited CTL using a vaccine strategy based on the TLR9 agonist CpG. This vaccine was administered with or without prior depletion of CD25 + T-reg. Immunization led to a detectable CTL response against B16 following CpG treatment alone (Fig. 1B) . By combining CD25 depletion with CpG, a more robust response against B16 and TRP1 222 (Fig. 1B) was elicited.
We next tested whether immunization using more traditional techniques could lead to the generation of these CTL by challenging mice with B16-CL emulsified in Titermax adjuvant and restimulated in vitro with either TRP1 222 or TRP2 180 pulsed stimulators. Splenocytes from B16-CL immunized mice that were restimulated with TRP1 222 or TRP2 180 generated effectors that could target their cognate peptide, demonstrating that both of these T cells were primed with the B16-CL (Fig. 1C) . Thus, several vaccine strategies can give rise to T-cell responses against the native TRP1 222 epitope. However, only the TRP1 222 -specific CTL, generated in this manner, targeted B16.
Live tumor cells elicit responses against a low-affinity MHC ligand processed from TRP1. We considered the possibility that other TRP1 peptides might be targeted after challenge with B16. We used an algorithm-based strategy (21) to choose five additional H-2K
b peptides from TRP1 and tested whether challenge with B16 tumor or B16-CL elicited a response against these epitopes. Our live cell therapy elicited a focused response primarily directed against the epitope TRP1 222 ( Fig. 2A) . Consistent with previous findings (15) , immunization with B16-CL and immune-modulating B7-DCXAb generated a broader response, targeting TRP1 7 , TRP1 175 , TRP1 222 , and TRP1 396 .
Immunization can lead to the generation of CTL that may not necessarily target antigens presented by MHC class I on tumors. Therefore, we generated TRP1 222 -specific CTL using peptide immunization to determine whether these CTL can target the TRP1 222 epitope processed from B16. The TRP1 222 CTL were able to kill B16 (Fig. 2B ), demonstrating that this antigen is indeed presented by B16 and is potentially a relevant tumor target.
Homologous sequences derived from other melanoma antigens could potentially mimic TRP1 222 surface presentation. Therefore, we transfected the syngeneic fibroblast line C57SV with a fulllength TRP1 clone to confirm that CTL can target the epitope derived from TRP1. TRP1 222 CTL killed the TRP1-transfected cells but not the untransfected control line nor a line transfected with a mutant TRP1 containing a noncanonical H-2K b anchor residue at position 226 of the TRP1 222 epitope (Fig. 2B) , demonstrating that the low-affinity TRP1 222 epitope is processed and presented from the TRP1 molecule.
One factor governing the presentation of a particular peptide is its ability to stabilize MHC class I before presentation on the cell surface. We performed stabilization assays using the transporter associated with the antigen processing-deficient line RMAS to evaluate the MHC binding affinity of potential TRP1-derived epitopes (17) and determined EC 50 values using regression analysis. We chose VSV 52 as a reference (22) , which stabilized H-2K b in the Figure 2 . B16 challenge induces CTL that recognize a low-affinity MHC class I ligand presented by the B16 tumor line. Cytotoxicity assays were performed as in Fig. 1 . A, EL4 target cells were pulsed with H-2K b -binding peptides from TRP1, and CTL were from draining lymph nodes of mice treated with B7-DCXAb using live B16 (black columns ) or B16-CL (gray columns ) as antigen. B, CTL generated from the spleens of TRP1 222 -immunized mice were used to assess presentation of the TRP1 222 epitope. Targets were TRP1 222 -and VSV 52 -pulsed EL4 or B16 tumor cells (left ) or C57SV fibroblasts transfected with a full-length TRP1, a TRP1 H-2K b anchor residue mutant, or nontransfected C57SV (right ). C, peptide binding to H-2K b was assessed by the change in mean fluorescence intensity (MFI ) from peptide-versus nonpeptide-pulsed RMAS cells. Data are representative of three independent trials. Symbols represent the change in MFI over a range of peptide concentrations for the indicated peptides. (Fig. 2C) . The previously identified melanoma peptide TRP2 180 stabilized H-2K b in the 100 nmol/L range, whereas the TRP1 222 peptide was effective in the 7,000 nmol/L range, confirming the reported low affinity of this ligand for the H-2K b allele. We also analyzed the array of TRP1 peptides for their ability to stabilize H-2K b ( Fig. 2A) . All of the epitopes targeted by B16-CL-induced CTL stabilized H-2K b with affinities in the 500 to 7,000 nmol/L range as determined by nonlinear regression analysis (Fig. 2C) . Those not targeted by CTL have affinities lower than 10 4 nmol/L. Therefore, whereas the ability to bind MHC class I molecules may be an important feature of immunogenic peptides, the range of required binding affinity seems to be quite large.
The epitope TRP1 222 is an immunodominant antigen mediating B16 tumor protection. To determine whether CTL specific for this low-affinity peptide are important for tumor clearance, we depleted TRP1 222 -specific T-cell responses in vivo by pretreating animals with soluble peptide before immunization. In mice pretreated with an irrelevant peptide, B16 or B16-CL challenge elicited CTL that targeted B16 as well as TRP1 222 (Fig. 3A) . Pretreatment with TRP1 222 blocked the development of TRP1 222 -specific CTL. This blockade completely inhibited in vitro killing of B16 when mice were challenged with B16 and B7-DCXAb (Fig. 3A) . Mice challenged with B16-CL and antibody generated TRP2 180 and gp100 25 CTL when a response to the immunodominant peptide was suppressed, indicating that TRP1 222 CTL outcompete these responses, as no reactivity against these epitopes was observed with B16-CL immunization (Fig. 1A) . In addition, B16 killing was inhibited by >50% when B16-CL was used as the vaccine antigen, demonstrating that TRP1 222 CTL represent a substantial component of this response.
Because TRP1 222 CTL are important for killing B16 in vitro, we tested whether these T cells were important for modulating antitumor protection. Accordingly, we used the peptide to block the induction of TRP1 222 -specific T cells before challenge with B16 tumor. Tumors failed to grow in animals pretreated with control peptide before B7-DCXAb immune modulation (Fig. 3B) . In contrast, mice depleted with TRP1 222 grew tumors despite B7-DCXAb treatment, with tumor growth kinetics similar to the growth in mice treated with control antibody. Because TRP1 222 depletion did not completely suppress B16 killing by CTL (Fig. 3A) , we tested whether the response against TRP1 222 was critical for the protection in B16-CL-induced vaccines. After peptide depletion, animals were treated with B16-CL and B7-DCXAb then challenged with live B16. Animals pretreated with the control peptide were protected from tumor outgrowth by the B16-CL vaccine. However, the TRP1 222 -depleted group developed tumors, similar to control mice, demonstrating a critical role of TRP1 222 CTL in B16-CL induced vaccines (Fig. 3C) .
The antigenicity of B16 melanoma tumor changes in response to irradiation, IFN; and in vivo growth. In contrast to our findings, previous reports have identified the melanoma differentiation proteins TRP2 180 and gp100 25 as important antigens in B16 melanoma (1, 2) and had designated unmodified TRP1 222 as a very weak antigen (3). We hypothesized that a vaccine using irradiated cells may target different antigens than vaccines elicited with nonirradiated cells. To test this, we used irradiated B16 cells (gIR-B16) in conjunction with B7-DCXAb as a vaccine. The elicited CTL targeted B16 as well as TRP1 222 , TRP2 180 , and gp100 25 ( Fig. 4A) . BecausegIR-B16 can induce a T-cell response against TRP2 180 , we wondered whether this treatment would also lead to the presentation of TRP2 180 on the surface of B16. TRP1 222 -specific CTL targeted the B16 cell line and gIR-B16 (Fig. 4B) . In contrast, TRP2 180 CTL did not kill the unmanipulated B16 tumor cells or the control line C57SV but killed gIR-B16. Therefore, irradiation of B16 tumor cells changes the spectrum of expressed antigens.
The induction of epitope-specific CTL after challenge with B16 melanoma tumors using various vaccine strategies have been were assessed for target specificity using B16 or peptide-pulsed C57SV targets. B, TRP1 222-229 (left) and TRP2 180-188 (right ) CTL were used to assess antigen presentation by unmanipulated B16, gIR-B16, and control C57SV targets. C, CTL as in B were used to determine antigen presentation in unmanipulated B16, IFNg-treated B16, and control C57SV targets. D, B16 tumors grew in situ for 5 d before B7-DCXAb treatment. Six days later, CTL were tested for specificity using B16 and EL4 (left) and TRP1 222 -, TRP2 180 -, or gp100 25 -pulsed EL4 (right ). (Fig. 4C) . Consistent with previous results, TRP2 180 CTL did not target the unmanipulated B16 cells; however, pretreatment with IFNg resulted in TRP2 180 -specific killing of the melanoma line.
We have shown that treatment with B7-DCXAb alone can lead to the clearance of established B16 tumors (12) . Because antigen expression patterns by growing tumors can be dynamic, we compared the antigen specificity of CTL induced by established and freshly challenged tumor (Fig. 1A) . Mice were challenged with Figure 5 . TRP1 222 -specific CTL induced with B7-DCXAb eradicate established B16 tumors. A, animals were depleted with TRP1 222 , TRP2 180 , or VSV 52 1 d before challenge with B16. On day 4, the depleted animals were treated with B7-DCXAb; CTL activity was assessed 6 d later for specificity using B16 and TRP1 222 , TRP2 180 -pulsed, or unpulsed EL4 targets. B, tumor-challenged animals were monitored for survival as in Fig. 2 (P < 0.001 TRP1 222 versus VSV 52 or TRP2 180 depletion). C, tumor growth in individual mice treated with TRP1 222 -, TRP2 180 -, gp100 25 B16 for 6 days before treatment with B7-DCXAb. On day 12, CTL effectively killed the B16 tumor, as well as cells pulsed with TRP1 222 , TRP2 180 , and gp100 25 (Fig. 4D) , demonstrating that melanoma growing in situ can prime T cells to several antigens.
Clearance of established B16 tumors using B7-DCXAb therapy is dependent on TRP1 222 CTL. Our hypothesis that TRP1 222 is the major tumor antigen in this model is challenged by the finding that the TRP2 180 and gp100 25 antigens can serve as potential targets in established tumors. Because TRP1-specific responses are elicited by established tumor, we asked whether depletion of TRP1 222 CTL would inhibit tumor rejection after B7-DCXAb therapy. To address this, we depleted TRP1 222 -, TRP2 180 -, or VSV 52 -specific T cells with peptide 1 day before B16 challenge and treated the mice with B7-DCXAb 4 days later. Sentinel mice were assessed on day 10 verifying peptide-specific depletion of CTL. TRP1 222 -depleted mice did not target TRP1 222 or B16, but targeted TRP2 180 . Similarly, TRP2 180 -specific responses were inhibited by TRP2 180 peptide, whereas the TRP1 222 and B16 responses remained. Pretreatment with irrelevant VSV 52 resulted in CTL that continued to target TRP1 222 -and TRP2 180 -pulsed EL4 cells, as well as the B16 tumor, but not EL4 cells (Fig. 5A) . TRP1 222 -depleted animals evaluated for tumor growth succumbed by day 20. In contrast, mice depleted with TRP2 180 survived for the extent of the observation period (Fig. 5B) , similar to the B7-DCXAb treatment group.
We then asked whether the generation of a monospecific TRP1 222 response is sufficient to clear established tumors. We treated bone marrow-derived dendritic cells with B7-DCXAb (DC XAb ) or control IgM (DC Ctrl ) ex vivo before pulsing with peptide and adoptive transfer into tumor-bearing mice. Animals vaccinated with DC XAb pulsed with TRP1 222 remained free of measurable tumor, whereas tumors grew progressively in mice treated with DC XAb pulsed with the melanoma peptides TRP2 180 and gp100 25 or the control peptide VSV 52 ( Fig. 5C and D) . This shows the importance of antigen specificity in this treatment regimen.
As a complementary approach, we generated TRP1 222 and TRP2 180 monospecific T cells and assessed their ability to lyse melanoma peptide-pulsed cells in a CD8-dependent and H-2K bdependent manner (Fig. 6A and B) , demonstrating their classic CTL functions. When these cells were transferred into mice 5 days after challenge with B16 tumor, animals receiving either no T cells or cells specific for TRP2 180 succumbed to tumor by day 20, whereas those receiving TRP1 222 T cells remained tumor-free (Fig. 6C) .
Discussion
The immunodominance of the low-affinity MHC class I ligand TRP1 222 tumor clearing response induced with native tumor antigens was remarkable, particularly as it occurred in the relative absence of responses against important targets of cellular immunity previously defined using the B16 melanoma tumor model. The paradigm that effective antigens bind efficiently to MHC-encoded antigen-presenting molecules has been used to identify several immunodominant viral antigens (24) . Therefore, high-affinity peptide ligands of tumor origin have been targeted in vaccine development. However, these antigens are naturally presented to the immune system in the absence of frank danger signals, before vaccination, resulting in the induction of tolerance. Consequently, high-avidity T cells specific for these tumor antigens may have been depleted from the immune repertoire. Tumor immunotherapy strategies have focused on recruiting the remaining low-to medium-avidity T cells using high-affinity MHC peptide ligands, with the hope that these T cells might be effective. Unfortunately, therapies based on this approach have failed.
Our findings support an alternative approach, eliciting highavidity, protective T-cell responses using low-affinity MHC peptide antigens. Low-affinity MHC ligands do not naturally deplete the high-avidity T cells, making appropriate T cells available for generating an effective antitumor response. One strategy to elicit strong T-cell responses to weak MHC ligands has been to use selfpeptide heteroclitic mimics as antigens. However, recent studies show that immunization strategies using native or heteroclitic antigens elicit distinct CTL responses, and immunization with native antigen preferentially induces high-avidity T-cell responses (25) with increased tumor recognition (26) in comparison with immunization with altered peptides.
Previous reports (3, 6, 27, 28) have identified TRP1 as a target for tumor immunotherapy. Melanoma patients develop IgG antibodies to TRP1, implying recognition of this melanoma differentiation antigen by CD4 + T cells. CD8 + T cells capable of recognizing TRP1 peptides are present in the immune repertoire and have been activated using xenogenic human and heteroclitic variants of mouse peptides. We find that native antigen derived from live, irradiated, or lysed tumor cells can activate strong CTL responses against TRP1. The precise nature of the TRP1 antigen that reaches the lymph node is not known. TRP1 can be secreted (29) , possibly gaining access to the lymph node faster than cell-associated antigens. We previously identified biochemical differences in recognized antigens derived from live tumors versus tumor lysates (15) , suggesting that negatively charged moieties, consistent with mature sialylated TRP1 molecules, may be targeted more efficiently after challenge with live tumor cells. Importantly, native TRP1 is processed and cross-presented by dendritic cells in a manner promoting the activation of CD8 + T cells specific for this lowaffinity MHC class I ligand.
Another important finding in this report is that other wellknown melanoma antigens were not targeted using B7-DCXAb to incite immunity against B16 tumor cells. Earlier studies used manipulated B16 cells to identify tumor antigens (1) . Gamma irradiation can modulate the repertoire of MHC class I peptides presented by tumor cells (30) . We also find that irradiated B16 tumor cells or tumors grown in situ for 6 days elicited responses against several antigens. Nevertheless, depletion of the TRP2 180 -specific T-cell response did not affect B7-DCXAb therapy in the established tumor model, whereas T cells targeting TRP1 222 were effective at eliminating the tumor. Although our protocol for generating adoptively transferred TRP2 180 -specific T cells may have been biased toward the generation of low-avidity T cells (31) , this study shows that at equimolar concentrations of the peptide, TRP1 222 peptide elicits T cells that are very effective at targeting and clearing B16. The importance of TRP1 in providing a survival advantage to melanomas has been suggested in studies of TRP1 mutations (32) and should be considered as a factor in the therapeutic effectiveness of this particular antigen. In our survey of B16 melanomas, TRP1-specific CTL kill B16, B16-OVA, B16-F10, as well as B16 cells that have been irradiated or established for 6 days in vivo. In contrast, TRP2 180 -specific CTL do not kill freshly cultured B16 but recognize tumor cells that have been irradiated, treated with IFNg, or established in vivo. We surmise that TRP1 222 -specific CTL responses can clear all tumor cells, whereas TRP2 180 -specific CTL may only be able to kill stressed cells, leaving behind seeds of healthy cells that sustain tumor growth.
This study supports challenges to the paradigm that high-affinity peptide ligands make effective vaccines for tumor therapy. It may be useful to develop strategies that can identify lower-affinity peptides that elicit curative T-cell responses. This task is difficult because the generation of MHC/tetramers or pentamers needed to track T cells specific for low-affinity MHC ligands is problematic. Identification of relevant peptides by acid elution and mass spectrometry would be expected to generate a bias toward peptides that bind to MHC class I with higher affinity, therefore missing peptides with the binding affinity characteristic of TRP1 222 . Further investigation must focus on alternative aspects of peptide immunogenicity, including the biochemical processing and subcellular characteristics of the antigens that liberate these MHC ligands. For example, we have found an increased sensitivity of TRP1 222 generation to protein synthesis inhibitors compared with other melanoma antigens, 1 demonstrating that rapid protein turnover may be important for presentation of this epitope.
The finding that a weak-binding self-peptide can be the target of effective antitumor immunity could have far-reaching implications. Genetic changes that lead to cancer, particularly those that escape immune surveillance, will not likely generate new high-affinity MHC ligands. In the rare cases when new high-affinity ligands are generated, they would be encountered first by the immune system in the absence of costimulation, leading to tolerance. The likelihood of generating new peptides with low affinity for MHC antigen-presenting molecules is higher, and the expectation is that high-affinity T cells present in the peripheral repertoire would be available for activation provided optimal activation signals are delivered. Here, we show that a protective and therapeutic CTL response against the native form of a low-affinity MHC ligand can be elicited using a variety of immunization schemes, including the immune modulator B7-DCXAb. These studies emphasize that the selection of effective tumor antigens goes beyond the identification of epitopes that can bind MHC with high affinity. Additional factors, including the structure of the processed antigen, availability of the antigen to the immune system, and the ability to recruit high-avidity T cells, can be crucial to the development vaccines that are not only effective immune stimulants but are also curative.
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